2010
DOI: 10.1111/j.1540-8159.2010.02935.x
|View full text |Cite
|
Sign up to set email alerts
|

Flecainide‐Associated Bradycardia‐Dependent Torsade de Pointes: Another Potential Mechanism of Proarrhythmia

Abstract: Although flecainide has a risk of proarrhythmia in patients with structural heart disease, its mechanism has been mainly ascribed to use-dependency and a rapid ventricular response to organized atrial tachyarrhythmias or to ventricular tachycardia. We present a patient who experienced recurrent syncope due to bradycardia-dependent torsade de pointes (TdP) associated with flecainide-related bradycardia and QT prolongation. Bradycardia-dependent TdP with QT prolongation can be considered as one of mechanisms of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 9 publications
0
7
0
Order By: Relevance
“…In human patients, flecainide increases the RV monophasic action potential duration and prolongs QT interval . Arrhythmogenic responses to flecainide are facilitated in the presence of well‐known torsadogenic risk factors, such as bradycardia, hypokalaemia, and previously unsuspected long QT syndrome gene mutations, which is in support of the role played by reduced repolarization reserve in adverse effects associated with flecainide therapy.…”
Section: Arrhythmogenic Responses To Antiarrhythmic Drugsmentioning
confidence: 68%
See 1 more Smart Citation
“…In human patients, flecainide increases the RV monophasic action potential duration and prolongs QT interval . Arrhythmogenic responses to flecainide are facilitated in the presence of well‐known torsadogenic risk factors, such as bradycardia, hypokalaemia, and previously unsuspected long QT syndrome gene mutations, which is in support of the role played by reduced repolarization reserve in adverse effects associated with flecainide therapy.…”
Section: Arrhythmogenic Responses To Antiarrhythmic Drugsmentioning
confidence: 68%
“…Flecainide, nevertheless, remains one of the first‐line treatments for symptomatic atrial fibrillation in patients with structurally normal hearts . This practice, however, is increasingly challenged by clinical observations indicating that flecainide can induce VT, often in the form of torsade de pointes, in patients without coronary artery disease or severe heart failure . The Pediatric Electrophysiology Group reported on the relatively high incidence of flecainide‐induced proarrhythmia in young cardiac patients, presumably in the absence of advanced coronary atherosclerosis which is commonly seen in the elderly .…”
Section: Arrhythmogenic Responses To Antiarrhythmic Drugsmentioning
confidence: 99%
“…A database literature search revealed only three such cases in patients with no additional triggers (electrolyte imbalance or medications). In all three cases, it was preceded by a bradyarrhythmia, perhaps providing the substrate for QT prolongation . Our patient was undergoing vigorous exercise and was unlikely to have been bradycardic; however, we cannot discount the fact that the effects of flecainide could have been enhanced by his exercise, leading to a transient bradycardia that served as the substrate for the development of his torsades de pointes.…”
Section: Discussionmentioning
confidence: 80%
“…Interestingly, our patient had a prolonged QT, most notably around the time of his cardiac arrest, without an associated increase in QRS duration as would be expected given flecainide's mechanism of action. There is a paucity of published information regarding the association of flecainide‐induced QT prolongation and the development of torsades de pointes in patients with a structurally normal heart . A database literature search revealed only three such cases in patients with no additional triggers (electrolyte imbalance or medications).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation